Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-4 chemotherapy-free neoadjuvant HER2-targeted therapy study
NL-OMON53609Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab, pertuzumab and tucatinib in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence and severity of adverse events. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON53609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53609.